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Key Point 
• The CXCR4 mutations in the WHIM syndrome impair the stability of the T 
cell-Antigen Presenting Cell immunological synapse 
 
The WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) 
syndrome is a rare disease characterized by diverse symptoms indicative of 
aberrantly functioning immunity. It is caused by mutations in the chemokine 
receptor CXCR4, which impair its intracellular trafficking, leading to increased 
responsiveness to chemokine ligand and retention of neutrophils in bone 
marrow. Yet WHIM patient symptoms related to adaptive immunity, such as 
delayed IgG-switching and impaired memory B cell function, remain largely 
unexplained. We hypothesized that the WHIM-associated mutations in CXCR4 
may affect the formation of immunological synapses between T cells and antigen 
presenting cells (APC). We show that, in the presence of competing external 
chemokine signals, the stability of T-APC conjugates from patients with WHIM-
mutant CXCR4 is disrupted due to impaired recruitment of the mutant receptor 
to the immunological synapse. Using retrogenic mice that develop WHIM-
mutant T cells, we show that WHIM-mutant CXCR4 inhibits the formation of 
long-lasting T-APC interactions in ex vivo lymph node slice time-lapse 
microscopy. These findings demonstrate that chemokine receptors can affect T-
APC synapse stability and allow us to propose a novel mechanism that 
contributes to the adaptive immune response defects in WHIM patients. 
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Introduction 
 
The rare human WHIM syndrome is characterized by neutropenia, myelokathexis, 
delayed antibody class switching to Immunoglobulin G (IgG)1, long-term 
hypogammaglobulinemia and memory B cell lymphopenia,2 recurring infections and 
human papillomavirus-induced warts.3 WHIM is associated with C-terminal, 
dominant mutations in the chemokine receptor CXCR4, resulting in truncation of the 
receptor.4 This leads to defective recycling upon binding of the CXCR4 ligand, 
CXCL12, and thus increased responsiveness to CXCL12 stimulation.2,5,6 The 
hyperfunctional CXCR4 mutations may thus explain neutrophil retention in the bone 
marrow (myelokathexis), where CXCL12 is expressed,7 and the consequent 
neutropenia in the periphery.8 However, the mechanism of pathogenesis of the 
remaining WHIM symptoms is less clear.3  
 
Recurrent infections, the delay in production of IgG-switched antibodies found in one 
study1 as well as the impaired memory B cell function and lack of long-term antibody 
titers following immunization,2 are indicative of defects involving the adaptive 
immune response, required for effective and lasting defense against invading 
pathogens. The initiation of the adaptive response involves antigen-specific activation 
of T cells in the secondary lymphoid organs, where APC home to after taking up 
antigen in the periphery. Following successful activation via a T cell-APC 
immunological synapse formation, antigen-activated CD4+ T cells can then provide 
co-stimulatory signals to B cells, which enable the B cells to undergo 
immunoglobulin class switch recombination and thus synthesize IgG, IgA and IgE.9 
The resultant memory B cells and plasma cells subsequently migrate to their niches.1 
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It has been proposed that, in a manner analogous to the effect on neutrophils, WHIM-
mutant CXCR4 on B cells may account for both the initial delay in mounting an IgG 
antibody response and the long-term memory B cell dysfunction, by affecting the 
homing of the B cells.1 
 
We have previously demonstrated that chemokine receptors, in addition to controlling 
leukocyte homing and migration, may increase the stability of the T cell-APC 
immunological synapses,10 the specialized junctions that form at the initiation of 
adaptive immune responses and which are necessary for successful T cell 
activation.11,12 Indeed, in vitro studies have led to the hypothesis that chemokines in 
lymph nodes may either enhance the stability of the synapse -by reinforcing the 
“stop” signal transduced by the antigen-triggered T cell receptor (TCR)- or inhibit T-
APC interactions -by providing “go” signals overcoming the TCR-.13-15 Whether this 
regulates T cell activation in vivo is still unknown.  
 
Given the hyperfunctional nature of WHIM-mutant CXCR4,2,5 we hypothesized that 
the WHIM-associated mutations in CXCR4 may interfere with the robustness of the T 
cell-APC synapses. This would be expected to affect T cell activation, as well as the 
B cell functions that are dependent on T cell activation, such as immunoglobulin class 
switching. Here we show that the WHIM-associated mutations of CXCR4 impair T-
APC synapse stability and may be affecting T cell priming, while causing a delay in 
IgG responses. These findings identify a novel mechanistic explanation for the defects 
in the early stages of adaptive immune responses in the WHIM syndrome, whilst also 
offering a novel and natural demonstration of the role of chemokines in the regulation 
of the immunological synapse stability. 
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Methods 
 
Retrogenic mice 
Animals were kept in an SPF facility and treated according to Institutional and 
National guidelines and regulations. Retrogenic mice were created as in16: bone 
marrows (BM) were harvested from donor OT-II ovalbumin (OVA)-specific TCR-
transgenic CD45.1 mice, that had been pre-treated with 5-fluoracil at 5.5mg/25g 
mouse, 4 days prior to harvesting. Harvested BM cells were grown in 20ng/ml rmIL-
3, 50ng/ml rmIL-6 and 50ng/ml rmSCF (all R&D Systems) for 48h and then 
transduced with retroviral vectors for EGFP-WT-CXCR4 or EGFP-WHIM-CXCR4 
and pCLEco (Imgenex) on day 2, 3 and 4 post-BM harvesting, using fresh viral 
supernatants, as in17. The transduced BM cells were kept in culture for a further 2 
days prior to intravenous injection into irradiated  (2x475 Rad) C57BL/6 recipients. 
These recipients were used as retrogenic mice, 7 weeks post-intravenous injection. 
 
T cell purification 
Patient and healthy donor samples were obtained after informed consent at Clinica 
Pediatrica and Humanitas, according to the institutional ethical committee guidelines 
and the Declaration of Helsinki. Primary human CD4+ T cells from peripheral blood 
were isolated using RosetteSep (StemCell Technologies), at a typical purity of >90%. 
CD4+ T cells were transduced with CXCR4 constructs using Amaxa human T cell 
nucleofector (Lonza). For experiments with patient samples, PBMC from WHIM 
patients and healthy age/gender-matched donors where expanded for 2 weeks after 
activation with 2.5 μg/ml PHA (Biochrom AG), 400 U/ml IL-2 (Chiron) and 
irradiated feeders; CD4+ T cells were then isolated using a FACSAria (BD) cell 
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sorter. Mouse CD4+ T cells from retrogenic mice were harvested at 7 weeks after 
bone marrow transfer, purified using MACS CD4+ kit (Miltenyi Biotec) and then 
sorted for EGFP expression on FACSAria. For lymph node slice time-lapse 2-photon 
imaging experiments, the CD4+ EGFP+ WT or WHIM-mutant CXCR4-expressing 
retrogenic cells were labeled with 2µM CFDA-SE (carboxyfluorescein diacetate 
succinimidyl ester) (Invitrogen). EGFP- non-retrogenic T cells were labeled with 
10µM Blue-CMAC (7-Amino-4-Chloromethylcoumarin) (Invitrogen) and used as a 
control population. Changing the dye used in the experimental populations did not 
modify the result. Nonetheless, as an additional measure, we chose to use the same 
dye for the 2 experimental populations, in order to ensure that no differential toxic 
effects of the two dyes could affect measurements. As this necessitated imaging of the 
2 populations in consecutive slices, the same Blue-CMAC-labeled, non-retrogenic 
control population was used as an internal control in both cases.  
 
T cell-APC conjugates  
The conjugate stability assay by transwell migration and the analysis of receptor 
recruitment to the synapse were adapted from10, with the following modifications: 
conjugates were formed between WT or WHIM-mutant CXCR4-expressing CD4+ T 
and primary B cells obtained via RosetteSep (StemCell Technologies). B cells had 
been pulsed with superantigen (1μg/ml staphylococcal enterotoxin A/B/E, Toxin 
Technology) and labeled with PKH26 dye (Sigma) and were used at a 1:1 ratio with T 
cells. Cells were then allowed to migrate through 3μm pores to 2.5nM CXCL12 
(R&D Systems) for 2h, before analyzing by FACS. Conjugates prepared for confocal 
microscope analysis of receptor recruitment were made using EBV-B as APC, and 
allowed to form in the presence or absence of CXCL12 (5nM-100nM) and AMD3100 
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(Sigma, 12.6μM). Relative Recruitment Index (RRI) for EGFP-CXCR4 was 
calculated as in10.  
 
Two-photon microscopy imaging 
Lymph node slice preparation was adapted from18. Bone marrow-derived dendritic 
cells (DC) were pulsed with 10μg/ml OVA(323-339)(Anaspec), labeled with 5μM 
CMTMR (5-(and-6)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine) dye 
(Invitrogen) and injected along with 40ng LPS (Sigma) at 4X106 cells/mouse 
subcutaneously into C57BL/6 mice. The following day the recipients were sacrificed 
and inguinal lymph nodes were extracted, enclosed in agarose and sliced using a 
vibratome (Leica VT 1000S). Labeled T cells from retrogenic mice were allowed to 
enter the lymph node for 1h prior to 3-colour time-lapse imaging for 30 minutes with 
a 30 second inter-frame interval on a LaVision TrimScope 2-photon microscope. As 
in18, the lymph node slices were placed in AMD3100 (Sigma, 12.6μM); to avoid the 
reported inhibition of entry into the lymph node slice, T cells were allowed 30 min in 
AMD3100-free medium to enter to the lymph node, followed by 30 min incubation in 
the presence of the inhibitor. AMD3100 was also present in the perfusion medium. 
Image analysis was performed on Imaris (Bitplane), using manually-corrected 
automatic tracking, and manual calculation of T-DC interaction times.  
 
Activation experiments 
T cell priming was performed by injecting 500ng OVA peptide in CFA into each hind 
footpad of WT or WHIM retrogenic mice. Draining lymph nodes and spleen were 
analyzed by FACS 12h after injection, for the expression of EGFP and staining for 
CD45.1 (A20; eBiosciences), CD4 (GK1.5; BioLegend) and CD69 (H1.2F3; BD). 
 For personal use only. at BIBLIOTECA POLO SAN PAOLO on July 3, 2013. bloodjournal.hematologylibrary.orgFrom 
 8 
Immunizations for IgG production experiments were performed as in19, using 
100μg/mouse of NP(4-hydroxy-3-nitrophenylacetyl)-OVA (Biosearch) in Imject 
Alum (Pierce). ELISA assays for the detection of anti-NP IgG were adapted from20, 
coating plates with 10μg/ml NP-BSA (Biosearch, Ratio>20) and detecting with Anti-
mouse IgG-Peroxidase (Sigma). Human primary T cell activation by anti-CD3/anti-
CD28 and IFNγ detection by ELISA was performed as in10. For mouse in vitro APC-
free T cell activation, 2μg/ml anti-CD3e (145-2C11; BD) and 1μg/ml anti-CD28 
(37.51; BD) were used for coating flat-bottom 96 well plates. The activation of rgWT 
and rgWHIM T cells by DC (at a 2:1 ratio) in the presence or absence of 25nM 
CXCL12 in the lower chamber of transwell assay plates was analyzed by FACS after 
staining for CD25 (PC61.5; eBiosciences). 
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Results 
 
WHIM-mutant CXCR4 disrupts the stability of T cell-APC conjugates in WHIM 
patients  
Given the association of the WHIM-mutant CXCR4 with enhanced chemotactic 
properties,2,5 we decided to assess whether the mutant chemokine receptor could 
impair the stability of the T-APC interaction in WHIM patients. Peripheral blood 
CD4+ T cells purified from a WHIM patient (G336X) or a healthy age- and gender-
matched donor were used in conjugate stability experiments.10 T cells were allowed to 
form conjugates with labeled, superantigen-pulsed primary B cells. Non-pulsed B 
cells, which cannot form successful T-B conjugates, were used as controls. The 
conjugates were then allowed to migrate in a transwell assay towards CXCL12, using 
a transwell filter pore size allowing only single cells to pass through. The number of 
migrated CD4+ T cells is thus an indication of lack of conjugate stability.10 As 
expected, T cells from healthy donors were significantly impaired from migrating to 
CXCL12 when superantigen-pulsed B cells were used for conjugate formation, 
suggesting that “go” signals delivered by wild-type (WT) CXCR4 are subordinate to 
the “stop” signal delivered by the antigen-triggered TCRs (Figure 1A, left panel), in 
agreement with previous in vitro studies.13 However, under the same conditions, the 
chemotactic response of T cells from WHIM patients was strong and undiminished by 
the presence of antigen-loaded APCs (Figure 1A, right panel). The values shown are 
normalized to enable comparison between different donors. Thus, WHIM patient 
CD4+ T cells exhibit impaired conjugate stability in the presence of competing 
external CXCL12 signals.  
 
 For personal use only. at BIBLIOTECA POLO SAN PAOLO on July 3, 2013. bloodjournal.hematologylibrary.orgFrom 
 10
Expression of WHIM-mutant CXCR4 disrupts the stability of T cell-APC 
conjugates in healthy donor cells 
To prove that this is indeed due to the mutant CXCR4, we cloned the WT and 
WHIM-mutant (R334X) versions of CXCR4 fused with Enhanced Green Fluorescent 
Protein (EGFP). The ectopically expressed receptor was functional, as it could lead to 
phosphorylation of MAP kinases after CXCL12 administration (data not shown). 
Importantly, the WHIM-mutant CXCR4 was refractive to ligand-induced 
internalization (supplemental Figure 1), which is a hallmark of the WHIM 
syndrome.5,6 We expressed WT or WHIM-mutant CXCR4 in primary CD4+ T cells 
from healthy donors and used them in conjugate stability experiments, as above. As 
the WHIM mutation is dominant,3 endogenous WT CXCR4 expression in transfected 
cells is unlikely to interfere with the experimental outcome. CXCL12 was able to 
break conjugates formed with T cells expressing the WHIM-mutant but not with WT 
CXCR4 (Figure 1B). This demonstrates that the WHIM-mutant CXCR4 per se has 
destabilizing effects on the immunological synapse when exposed to competing 
cognate chemokine. As CXCL12 is present in the lymph node environment21 this 
“distracting” effect could impact on physiological T cell activation.  
 
WHIM-mutant CXCR4 affects T cell-APC long-lasting interactions  
To assess the physiological relevance of our findings, we tested our hypothesis 
utilizing ex vivo organ cultures of mouse lymph node slices.18,22 As human CXCR4 is 
functional in mice,8 we created retroviral versions of the CXCR4 constructs described 
above and used them to make retrogenic mice16 for WT or WHIM-mutant CXCR4. 
These mice generate mature, unactivated ovalbumin(OVA)-antigen-specific T cells 
expressing WT or WHIM-mutant CXCR4, 6 weeks after reconstitution of irradiated 
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recipients with transduced bone marrow cells16,23 (see Methods).  
The WHIM retrogenic mice showed a 4-fold increase in bone marrow retention of 
WHIM-mutant CXCR4-expressing leukocytes in sentinel animals (data not shown), 
similar to previously reported models.8 Nonetheless, the mice ought to be considered 
as “retrogenic cell generators” rather than disease models. Indeed, our intention was 
to analyze the effects of the WHIM mutations on T cell-mediated responses to 
antigenic stimulation, in a physiological environment but in the absence of additional, 
complicating variables that may be affected by WHIM-mutant CXCR4 expression on 
other tissues.  
From the retrogenic mice, we purified CD4+ T cells expressing retrogenic WT 
(rgWT) or WHIM-mutant (rgWHIM) CXCR4. OVA-specific T cells with no 
retrogenic expression were used as a control population. The T cells were labeled and 
allowed to enter into ex vivo organ cultures of lymph node slices,18,22 which had been 
extracted from mice that had received OVA antigen-pulsed, CMTMR-labeled 
dendritic cells (DC), on the previous day. The slices were imaged using 2–photon 
time-lapse video microscopy, starting 1 hour after administration of the T cell 
populations onto the lymph node slices. We analyzed all T cells that interacted with 
DC during the 30 minutes of each video. Control T cells, with no retrogene 
expression, formed more long-lasting interactions (clustering at ≥ 20 min) in the 
presence of OVA-pulsed as opposed to unpulsed DC (supplemental Figure 2), in 
agreement with previous reports.24 The difference in the number of long versus short 
interactions was significant (Figure 2A). T cells expressing rgWT CXCR4 exhibited 
an identical behavior (Figure 2A and Video 1-3), indicating that, in this assay, the 
retrogenic expression per se does not distort the physiological function of the cells. 
Interestingly, rgWHIM T cells did not show any significant increase in the number of 
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long-lasting interactions (Figure 2A; also plotted as % in Figure 2B; black bars; Video 
4-5) with antigen presence, thus confirming that the WHIM mutation impairs the 
ability of T cells to form long-lasting interactions with antigen-pulsed DC. In the 
presence of cognate antigen-pulsed DC the mean 3D speed of the WT cells was 1.7 
μm/min versus 2.3 μm/min for the WHIM T cells, which is consistent with the more 
frequent interactions of the latter with DC. 
As the observed impairment could be due to defective development of the rgWHIM T 
cells, we repeated the above experiments in the presence of AMD3100, a CXCR4 
inhibitor that is identical to FDA and EMEA approved drug plerixafor.25 In the 
presence of AMD3100, rgWHIM cells no longer differed from rgWT cells in the 
proportion of long-lasting interactions (Figure 3A; also plotted as % in Figure 3B; 
Video 6). Thus, the defective T-DC conjugate stability of rgWHIM cells was 
reversible within the lymph node slice and is therefore unlikely to be caused by 
upstream developmental defects. Although at very high concentrations, not achievable 
in vivo with the maximum FDA-approved dose, AMD3100 may act as a CXCR7 
agonist,26 the complete reversal of the phenotype caused by the mutant CXCR4 
suggests that, in this context, AMD3100 does indeed act as a CXCR4 inhibitor. Cells 
expressing WT CXCR4 were expectedly unaffected, as it has been shown that WT 
CXCR4 signaling within the lymph node microenvironment is inconsequential for T 
cell activation.18,27  
 
The recruitment of WHIM-mutant CXCR4 to the Immunological Synapse is 
disrupted by competing chemokine signals 
In order to gain insight on the mechanism that underlies the disruption of synapse 
stability by WHIM-mutant CXCR4, we examined the cellular distribution of the 
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receptor during T-APC conjugate formation. We expressed the EGFP-fused WT or 
WHIM-mutant CXCR4 in primary CD4+ T cells from healthy donors that were 
allowed to form conjugates with superantigen-pulsed EBV-B cells, in the presence of 
competing external chemokine ligand at a wide range of concentrations. We then 
analyzed the recruitment of the fluorescent CXCR4 molecules to the T-APC synapse 
by confocal microscopy. WT CXCR4 (Figure 4A, white bars) was significantly 
recruited to the synapse when superantigen-pulsed EBV-B cells were used, as 
previously shown.10 This recruitment was not significantly reduced by the presence of 
competing, external CXCL12 ligand in the culture medium, a finding that is 
compatible with the attribution of lack of “dominance” over TCR signals to WT 
CXCR4-CXCL12 interactions.14 Interestingly, whilst WHIM-mutant CXCR4 (Figure 
4A, black bars) was also significantly recruited to the synapse in the presence of 
superantigen, this recruitment was significantly reduced in the presence of competing 
CXCL12, suggesting a possible mechanistic explanation for the disruptive effect of 
the mutant receptor on immunological synapse stability. Furthermore, mirroring our 
ex vivo findings, concurrent presence of AMD3100 as well as CXCL12 in the culture 
medium was able to fully reverse the loss of mutant receptor recruitment to the 
synapse. 
 
WHIM-mutant CXCR4 leads to aberrant in vivo T cell priming and a delayed 
IgG response 
Even though not all stable T-APC conjugates would be expected to lead to the 
initiation of an immune response, a significant impairment in the stability of 
immunological synapses is likely to cause aberrant T cell activation in vivo.11,12 To 
test this in our system, we injected OVA peptide into the footpads of WHIM-mutant 
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or WT CXCR4 retrogenic mice and examined their EGFP-expressing, retrogenic T 
cells in draining lymph nodes, 12h after antigen administration. rgWT T cells 
displayed moderately yet significantly higher expression of the early T cell activation 
marker CD6928 than rgWHIM T cells (Figure 5A, right panel and 5B). In non-
draining lymphoid compartments, such as the spleen (Figure 5A, left panel), no 
difference was observed. These results suggest that WHIM-mutant CXCR4-
expressing T cells exhibit aberrant T cell priming. To understand whether this result 
may depend on intrinsic defects of the TCR/CD3 complex of rgWHIM T cells, we 
performed in vitro activation experiments using anti-CD3 and anti-CD28 antibodies. 
T cells from WHIM-mutant retrogenic mice, as well as WHIM patient (G336X) T 
cells, displayed fully functional TCR signalling (Figure 5C-D). Then, we tried to 
reproduce in vitro the conditions present during T cell activation in lymph nodes that 
may affect the stability of the synapse. T cells were stimulated with peptide-pulsed 
DCs in a transwell chamber (upper well), in the presence or in the absence of the 
“distracting” effects of CXCL12 (lower well). When CXCL12 was present in the 
lower chamber, rgWHIM but not rgWT T cells displayed a modest, although 
significant, reduction in activation (Figure 5E-F).  
 
To confirm the physiological relevance of our findings, we assessed whether the 
aberrant T cell priming could lead to T cell-dependent early activation defects that 
characterize WHIM syndrome patients, such as the delay in IgG responses found in 
one study.1 To this end, we transferred 25X103 OVA-specific rgWT or rgWHIM 
CD4+ T cells into RAG1-/- mice, which are devoid of functional T and B cells. To 
provide antibody-producing cells, we co-transferred 6X106 T-depleted lymphocytes 
from WT syngenic donors. The recipient mice were immunized intraperitoneally with 
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OVA coupled to the hapten NP. WT B cells that can recognize NP29 will take up NP-
OVA and present peptides from both NP and OVA to T cells. Co-stimulation of the B 
cells by the transferred OVA-specific retrogenic T cells, which will represent the vast 
majority of the T cells present, will enable B cells to undergo class switch 
recombination and produce IgG antibodies against NP. As expected from previous 
studies,29 by day 7 after immunization, recipients of rgWT T cells displayed a 
significant increase of anti-NP IgG in their sera (Figure 6, grey bars). However, this 
failed to occur in recipients of rgWHIM T cells, which did not mount a significant 
IgG response (Figure 6, black bars), remaining at levels found in T cell-depleted 
controls (data not shown). Yet by day 14 both groups of recipients displayed high IgG 
titers (Figure 6, day 14) and remained not significantly different in subsequent 
timepoints up to 6 months (data not shown). Thus the expression of WHIM-mutant 
CXCR4 on T cells leads to a delay in IgG responses, mirroring the delayed IgG 
switching observed in WHIM.1 
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Discussion 
 
The WHIM syndrome is characterized by symptoms affecting different stages of the 
adaptive immune response, the etiology of which is not clearly understood. 
Deficiencies in the late stages of adaptive responses include the memory B cell 
lymphopenia, inability to maintain long-term IgG antibody titers after immunization2 
and recurring infections.3 It has been proposed1 that these defects may be caused, in 
similarity to the aberrant neutrophil homing, by impaired memory lymphocyte 
homing, a hypothesis supported by the panleukopenia in peripheral blood of WHIM 
patients.2,25 On the other hand, the delay in mounting IgG antibody responses 
observed in a patient studied by Mc Guire and colleagues1 involves a T cell-
dependent, B cell-mediated process that occurs at the early stages of the adaptive 
response. Our study offers a novel mechanistic explanation, at the heart of adaptive 
immune response initiation, for this observation. We demonstrate that immunological 
synapse stability is impaired in the presence of WHIM-mutant CXCR4.  It is tempting 
to speculate that this is due to the lack of mutant receptor recruitment to the synapse, 
which, combined with the hyperfunctional nature2,5 of WHIM-mutant CXCR4 and the 
presence of CXCL12 in the lymph node,21 disrupts the TCR-mediated, synapse-
promoting signals. This does not preclude the parallel existence of additional 
mechanisms, such as the proposed CXCR4-mediated aberrations in lymph node 
architecture,1 which are in agreement with recent data from a mouse model of 
WHIM,30 even though studies of hypogammaglobulinemia have yet to be performed 
in the latter.31 Given the wide expression range of CXCR4, it is likely that the 
combined effect of the above mechanisms, including the defect in synapse stability 
described here, contribute to the complex symptoms of the WHIM syndrome.  
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In the physiological milieu where T-APC immunological synapses form, “dominant” 
chemokine signaling has been proposed to inhibit stable synapse formation, based on 
results of in vitro experimentation.14,15 CXCL12 interacting with T cells expressing 
WT CXCR4 was found not to be a “dominant” chemokine.13 Rather, CXCR4 is 
recruited to the immunological synapse itself, where it enhances the activation of the 
T cell after receiving chemokine ligand produced by the APC.10 Exogenous 
chemokine signals that are not derived from the APC but from the surrounding lymph 
node microenvironment, where the chemokine is present,21 indeed did not affect T-
APC synapse formation in WT CXCR4-expressing cells in our studies, in agreement 
with results showing lack of a role for WT CXCR4-CXCL12 on T cell activation.18,27 
Yet our in vitro and ex vivo results show that WHIM-mutant CXCR4 enables 
CXCL12 to act as a distracting, “dominant” chemokine. This appears to occur via the 
disruption of the recruitment of WHIM-mutant CXCR4 to the synapse. Both the 
disruption of the receptor recruitment to the synapse and the “distracting” of stable 
synapse formation appear to be reversible by AMD3100 treatment, which has recently 
been proposed as a therapeutic agent for the WHIM syndrome.25 Importantly, our 
findings also provide the first physiological, ex vivo evidence that chemokines and 
their receptors may control the stability of T-DC interactions in lymph nodes. The 
data suggest the existence of a delicate equilibrium between adhesive and 
chemoattractant forces operating in lymph nodes during T cell priming, allowing 
enough motility for T cell repertoire scanning whilst ensuring the formation of long-
lasting conjugates, once a cognate T-APC pair is formed. Variations in this 
equilibrium, such as those due to the hyperfunctional mutant CXCR4 of WHIM 
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patients3 may lead to impaired stability of the immunological synapse and 
consequently contribute to an aberrant adaptive immune response. 
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Figure Legends 
 
 
Figure 1. WHIM-mutant CXCR4 impairs T cell-B cell conjugate stability. (A) 
Primary CD4+ T cells from healthy WT donor or WHIM-patient peripheral blood 
formed conjugates for 15’ with superantigen (sAg)-pulsed, labeled primary B cells 
from a healthy allogenic donor. The conjugates were allowed to migrate towards 
CXCL12 in a transwell filter allowing the migration of single cells only. The migrated 
T cells were analyzed by FACS and the number of T cells migrated for each condition 
is shown. *, P < 0.05 (1-way ANOVA and Tukey’s post test). Experiment performed 
twice, summary of results (mean +/- SEM) shown. (B) Primary CD4+ T cells from 
healthy donor peripheral blood transfected with EGFP-CXCR4 (WT) or EGFP-
CXCR4 (WHIM) formed conjugates for 15’ with sAg-pulsed primary B cells from 
the same donor. The conjugates were allowed to migrate towards CXCL12 in a 
transwell filter allowing the migration of single cells only. Migrated EGFP+ T cells 
were analyzed as above. **, P < 0.01 (1-way ANOVA and Tukey’s post test). 
Experiment performed twice, results (mean +/- SEM) from representative experiment 
shown.  
 
Figure 2. WHIM-mutant CXCR4 impairs T-DC interactions in ex vivo lymph 
node slice cultures. See also Videos 1-5. DC were either cognate antigen-pulsed 
(OVA) or unpulsed (no pept). ctrl: non-retrogenic OVA-specific T cells. WT: OVA-
specific T cells retrogenically expressing WT CXCR4. WHIM: OVA-specific T cells 
retrogenically expressing WHIM-mutant CXCR4. (A) Duration of T-DC interactions 
within ex vivo lymph node slices imaged by 2-photon microscopy. Summary results 
of 2 videos per condition shown. Each dot represents a single T-DC interaction. (from 
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left to right, n=125, 101, 66, 21, 298, 291, 197 and 183). An independent experiment 
with the T cell populations labeled with different dyes yielded the same result. A 
Fisher’s exact test was applied to the number of interactions greater or equal to 20 
min versus the number of interactions shorter than 20 min. *, P < 0.05; **, P < 0.01; 
***, P < 0.001. (B) The percentage of T-DC interactions greater or equal to 20 min, 
out of all analyzed interactions. White bars: non-retrogenic OVA-specific control T 
cells. Grey bars: OVA-specific T cells retrogenically expressing WT CXCR4. Black 
bars: OVA-specific T cells retrogenically expressing WHIM-mutant CXCR4. The 
statistical analysis refers to the Fisher’s exact test, as in (A). 
 
Figure 3. WHIM-mutant CXCR4-mediated impairment of T-DC interactions in 
ex vivo lymph node slice cultures is reversed by the CXCR4 inhibitor AMD3100. 
See also Video 6. DC were either cognate antigen-pulsed (OVA) or unpulsed (no 
pept). ctrl: non-retrogenic control OVA-specific T cells. WT: OVA-specific T cells 
retrogenically expressing WT CXCR4. WHIM: OVA-specific T cells retrogenically 
expressing WHIM-mutant CXCR4. (A) Duration of T-DC interactions within ex vivo 
lymph node slices imaged by 2-photon microscopy, in the presence of 12.6μM 
AMD3100. Summary results of 2 videos per condition shown. Each dot represents a 
single T-DC interaction (from left to right, n=150, 103, 167, 158, 152, 301, 137 and 
178). A Fisher’s exact test was applied to the number of interactions greater or equal 
to 20 min versus the number of interactions shorter than 20 min. *, P < 0.05;  ***, P < 
0.001. (B) The percentage of T-DC interactions greater or equal to 20 min, out of all 
analyzed interactions. White bars: non-retrogenic OVA-specific control T cells. Grey 
bars: OVA-specific T cells retrogenically expressing WT CXCR4. Black bars: OVA-
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specific T cells retrogenically expressing WHIM-mutant CXCR4. The statistical 
analysis refers to the Fisher’s exact test, as in (B). 
 
Figure 4. WHIM-mutant CXCR4 recruitment to the T-APC synapse is impaired 
by competing external CXCL12 and restored by AMD3100. (A) Primary CD4+ T 
cells from healthy donor peripheral blood transfected with EGFP-CXCR4 (WT) or 
EGFP-CXCR4 (WHIM) formed conjugates for 15’ with unpulsed or superantigen 
(sAg)-pulsed EBV-B cells, in the presence or absence of 5nM to 100nM CXCL12 and 
12.6μM AMD3100. The cells were fixed, imaged in confocal microscopy, and the 
Relative Recruitment Index to the T-APC synapse (RRI) for EGFP-CXCR4 was 
calculated. The graph displays the percentage of cells with CXCR4 recruited to the 
synapse (i.e. with RRI above the mean RRI of control WT T cells incubated with 
unpulsed EBV-B). The RRI data set for all analyzed cells (n≥40 per condition) is 
shown in (supplemental Figure 3). Statistical analysis was performed on the 
proportion of cells displaying recruitment versus non-recruitment of CXCR4 to the 
synapse. *, P < 0.05, ***, P < 0.001 (Fisher’s exact test). (B) Representative confocal 
microscopy images showing the recruitment of EGFP-CXCR4 (WT) or EGFP-
CXCR4 (WHIM) to the T-APC synapse. 
 
Figure 5. Aberrant responses of WHIM-CXCR4 T cells due to reduced synapse 
stability. (A) WT or WHIM-CXCR4 retrogenic mice were immunized with OVA 
peptide in their hind footpads. Expression of early activation marker CD69 (anti-
CD69 antibody Mean Fluorescence Intensity) on retrogenic CD4+ T cells from the 
spleen or draining lymph nodes (popliteal) of immunized animals (n=5) at 12h post-
immunization is shown. A normality test was performed followed by an unpaired t-
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test: Popliteal P = 0.0015; spleen P = 0.9. (B) Representative histograms of CD69 
expression by EGFP+ CD4+CD45.1+ rgWT or rgWHIM T cells in the popliteal lymph 
nodes of the animals analyzed. (C) Healthy donor or WHIM patient (G336X) CD4+ T 
cells were activated by anti-CD3 and anti-CD28 coated beads. IFNγ production was 
measured by ELISA at 48h. Normalized results are shown to enable comparison of 
different donors. (D) rgWT or rgWHIM T cells were activated in tissue culture plates 
by anti-CD3 and anti-CD28. CD69 expression was measured at 12h. Anti-CD69 
antibody Mean Fluorescence Intensity on CD4+EGFP+ rgWT or rgWHIM T cells is 
shown. **, P < 0.01;  ***, P < 0.001 (1-way ANOVA and Tukey’s post test). 
Representative experiment of two experiments shown. (E) rgWT or rgWHIM T cells 
were placed with cognate antigen-pulsed (OVA) DC in the upper chamber of a 
transwell assay plate, whilst 25nM CXCL12 was added or not to the lower chamber. 
The cells were incubated for 2h in the transwell plates before being transferred to 
serum-containing wells for 12h. The number of CD25+ cells among EGFP+CD4+ T 
cells in pooled upper and lower chamber cells at the end of the incubation is shown in 
(E), normalized for differences in the transduction efficiency between the rgWT and 
rgWHIM donor mice. CD25 expression (anti-CD25 antibody Mean Fluorescence 
intensity) on EGFP+CD4+ T cells of pooled upper and lower chamber cells at the end 
of the incubation is shown in (F). For both *, P < 0.05 (repeated measures 1-way 
ANOVA). Experiment performed twice, summary of results (mean +/- SEM) shown. 
It is noteworthy that, in the absence of antigen, the rgWHIM T cells displayed a 
higher baseline CD25 expression. 
 
Figure 6. WHIM-CXCR4 expressing retrogenic T cells lead to a delay in IgG 
antisera production. RAG1-/- recipient mice (n=5 per group) were reconstituted with 
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retrogenic WT (rgWT) or WHIM (rgWHIM) T cells specific for OVA as well as T-
depleted splenocytes, and immunized with NP-OVA. The bars show anti-NP IgG 
titers in the sera at various timepoints after immunization. **, P < 0.01, ***, P < 
0.001 (2-way ANOVA and Bonferroni post tests). 
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